Lupin Limited
Lupin board will convene on May 7, 2026, to consider audited standalone and cons. financial results for FY26. The meeting will also include a recommendation for a final dividend for the period.
Apr 22 2026 22:04:00
Lupin Ltd - 500257 - Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2026, And Recommend Dividend, If Any.
Lupin's Board is scheduled to meet on May 7, 2026, to consider and approve the audited Q4 FY26 financial results. The meeting will also review potential dividend recommendations for shareholders.
Apr 22 2026 22:04:00
Lupin Limited
Lupin Limited launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. The launch follows U.S. FDA approval for its Abbreviated New Drug Application, making it bioequivalent to Xigduo® XR.
Apr 22 2026 09:04:00
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. This follows U.S. FDA approval for its Abbreviated New Drug Application, making it bioequivalent to Xigduo® XR.
Apr 22 2026 09:04:00
Lupin Limited
Lupin's Somerset, New Jersey facility underwent a US FDA inspection from April 13-17, 2026. The inspection concluded with a Form-483 with three observations, which the company will address within the stipulated timeframe.
Apr 18 2026 11:04:00
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Acquisition
Lupin incorporated 'Lupin (Thailand) Limited' on April 17, 2026, as a wholly-owned subsidiary to expand its pharmaceutical business. The new entity, capitalized at 3 million Baht, will import, market, and distribute pharmaceutical products in Thailand.
Apr 17 2026 17:04:00
Lupin Limited
Lupin Limited incorporated a wholly-owned subsidiary, Lupin (Thailand) Limited, on April 17, 2026, with a capital of 3 million Baht. This strategic move aims to expand the company's pharmaceutical import, marketing, and distribution network in Thailand.
Apr 17 2026 17:04:00
Lupin Limited
Lupin's US subsidiary, LPI, settled antitrust litigation with Humana Inc. for $30 million (USD). This settlement explicitly states that LPI denies all allegations of liability or unlawful conduct.
Apr 17 2026 06:04:00
Lupin Limited
Lupin's US subsidiary, Lupin Pharmaceuticals, Inc. USA (LPI), settled a civil antitrust lawsuit with Humana Inc. for $30 million. This resolves allegations of anticompetitive behavior, avoiding ongoing litigation costs, and was provisioned in prior financials.
Apr 17 2026 06:04:00
Lupin Ltd - 500257 - Settlement Agreement.
Lupin Pharmaceuticals, Inc. (LPI), a subsidiary, settled an antitrust lawsuit involving anticompetitive behavior for USD 30 million with Humana Inc. This amount was already provided for in the company's prior consolidated financial results, removing a legal overhang.
Apr 17 2026 06:04:00
Read More